VP3.15 Dihydrobromide manufacturers
- VP3.15 dihydrobromide
-
- $64.00 / 5mg
-
2025-05-06
- CAS:1281681-33-1
- Min. Order:
- Purity: 98%
- Supply Ability: 10g
|
| | VP3.15 Dihydrobromide Basic information |
| Product Name: | VP3.15 Dihydrobromide | | Synonyms: | VP3.15 Dihydrobromide;Glycogen synthase kinase-3,VP3.15 dihydrobromide,inhibit,Inhibitor,VP-3.15 dihydrobromide,Glycogen synthase kinase 3,GSK-3,Phosphodiesterase (PDE);N-(2-Morpholinoethyl)-2,3-diphenyl-1,2,4-thiadiazol-5(2H)-imine dihydrobromide;VP3.15 dihydrobromide, 10 mM in DMSO | | CAS: | 1281681-33-1 | | MF: | C20H23BrN4OS | | MW: | 447.4 | | EINECS: | | | Product Categories: | | | Mol File: | 1281681-33-1.mol |  |
| | VP3.15 Dihydrobromide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | dmso:62.5(Max Conc. mg/mL);118.3(Max Conc. mM) | | form | Solid | | color | Light yellow to yellow |
| | VP3.15 Dihydrobromide Usage And Synthesis |
| Description | VP3.15 Dihydrobromide is a novel dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor. | | Uses | VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1]. | | target | VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. | | References | [1] Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545. DOI:10.1038/srep43545 |
| | VP3.15 Dihydrobromide Preparation Products And Raw materials |
|